MGX Earnings Metagenomi Therapeutics, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–13 of 13
| Q1 2026 | 2026-03-31 | -0.61 | 2026-05-11 | 10-Q |
| FY 2025 | 2025-12-31 | -2.36 | 2026-03-05 | 10-K |
| Q3 2025 | 2025-09-30 | -1.76 | 2025-11-12 | 10-Q |
| Q2 2025 | 2025-06-30 | -1.21 | 2025-08-12 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.68 | 2026-05-11 | 10-Q |
| FY 2025 | 2024-12-31 | -2.36 | 2026-03-05 | 10-K |
| Q3 2025 | 2024-09-30 | -1.73 | 2025-11-12 | 10-Q |
| Q2 2025 | 2024-06-30 | -1.24 | 2025-08-12 | 10-Q |
| Q1 2025 | 2024-03-31 | -1.19 | 2025-05-13 | 10-Q |
| FY 2024 | 2023-12-31 | -20.05 | 2025-03-17 | 10-K |
| Q3 2024 | 2023-09-30 | -14.38 | 2024-11-13 | 10-Q |
| Q2 2024 | 2023-06-30 | -8.56 | 2024-08-14 | 10-Q |
| Q1 2024 | 2023-03-31 | -4.74 | 2024-05-14 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.